产品
编 号：F741447
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2238831-60-0
产品详情
生物活性：
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.
体内研究：
Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable.
体外研究：
Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro.
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.
体内研究：
Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable.
体外研究：
Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备